Vital Signs - Global Biosimilars Market: Patent Expiries of Blockbuster Biologics Provide Large Market Opportunity

 

Regular Price: USD 1,500

Special Price USD 1,125

25% OFF

* Required Fields

Regular Price: USD 1,500

Special Price USD 1,125

PAY BY INVOICE

Be the first to review this product

This issue of Vital Signs, released on June 20, 2012, provides an insight in to the global biosimilars market.

Additionally, a company spotlight is provided for Dragonfly Sciences. Dragonfly Sciences is a private biotechnology company specializing in the development of biosimilar monoclonal antibodies and soluble receptors. Reimbursement and regulatory news from the FDA is also provided for week of June 4, 2012.

Table of Contents

Vital Signs - Global Biosimilars Market: Patent Expiries of Blockbuster Biologics Provide Large Market OpportunityVital Signs: 20 June 2012This week's issue




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 07-Nov-17

Region : North America

Release Date : 06-Nov-17

Region : North America

Release Date : 31-Oct-17

Region : North America

Release Date : 30-Oct-17

Region : North America

Release Date : 25-Oct-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.